Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Q3 2021 Earnings Presentation
22 slides from Therapeuticsmd's earnings presentation, Nov 11, 2021
Slide 1: Building the Premier Women's Health Company: Q3 2021 Earnings
Building the Premier Women’s Health Company Q3 2021 Earnings November 11, 2021 FOR INVESTOR PRESENTATION PURPOSES ONLY.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as “we,” “our,” or “the Company”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statemen
Slide 3: Announcing: Hugh O'Dowd
Announcing: Hugh O’Dowd FOR INVESTOR PRESENTATION PURPOSES ONLY. 3
Slide 4: Immediate Priorities
Immediate Priorities 1 Drive top-line 2 Eliminate $60 million 3 Achieve EBITDA 4 Address capital growth and in annual costs in breakeven in the structure to ease overall operating 2022, including the second half of 2022 restrictive revenue performance successful divestiture and cash covenant
Slide 5: 3Q21 Financial Overview
3Q21 Financial Overview FOR INVESTOR PRESENTATION PURPOSES ONLY. 5
Slide 6: Quarterly Product Revenue Trends
Quarterly Product Revenue Trends Quarterly Product Revenue (YoY) 3Q21 Highlights $24.5 $25 Total net product revenue increased 41% Q321 vs Q320 $20 $17.3 ANNOVERA sales increased by 84% on strong volume growth Q321 vs Q320 Millions $15 IMVEXXY net revenue increased by 17% Q321 vs 3Q20 driven b
Slide 7: Financial Results: Comparison 3Q 2021 to 2Q 2021 and 3Q 2020
Financial Results: Comparison 3Q 2021 to 2Q 2021 and 3Q 2020 Comparison of Key Financial Statement Items [$000’s] Q 32 1 Q 2 21 Q 32 0 Net revenue of $25.4M was an increase of $6.1M Balance Sheet(1) compared to Q320 Cash $104,841 $111,424 $79,634 Debt $186,738 $185,261 $237,051 Gross margin of 7
Slide 8: Q3 2021 Commercial Overview
Q3 2021 Commercial Overview FOR INVESTOR PRESENTATION PURPOSES ONLY. 8
Slide 9: Mark Glickman
Mark Glickman 31 Years in the Pharmaceutical/Device Industry Career Highlights Started with Baxter Healthcare MBA Finance and International Management NYU Stern School of Business Bristol Myers Squibb Kos Pharmaceutical o Lead team on Plavix marketing o Launched company's second product o Launch
Slide 10: Commercial Vision
Focus on our Patients and Physicians Environment of Accountability Commercial Vision Create a Performance Based Organization that will Execute with Excellence Become the Premier Women’s Healthcare Commercial Organization FOR INVESTOR PRESENTATION PURPOSES ONLY. 10
Slide 11: Opportunities
Opportunities Three Adjusted differentiated approach Great team Barriers to Significant therapeutic post-covid committed to launch are managed care options for Transition to an HCP success removed and other wins women prioritized effort FOR INVESTOR PRESENTATION PURPOSES ONLY. 11
Slide 12: Initial Assessment
Initial Assessment Marketing programs Complex solution orientation Managed care was good, overweighted to consumer albeit in need of optimization FOR INVESTOR PRESENTATION PURPOSES ONLY. 12
Slide 13: Areas of Immediate Focus
Retarget and redistribute activity Areas of to highest decile physicians for all products Immediate Significant overhaul of effort Focus Roll out occurring in stages Clear direction and evaluation regarding call and all field activity Focus representatives on solution selling Build confidenc
Slide 14: Results
Results FOR INVESTOR PRESENTATION PURPOSES ONLY. 14
Slide 15: Calls per Day
Calls per Day September’s 9.2 average calls per day reflects an 11% increase versus August and the highest level in the past 6 months 10.0 9.5 9.2 9.0 Calls per Day 8.5 8.3 8.3 8.3 8.2 8.0 7.5 7.5 7.0 6.5 6.0 April May June July August September Month FOR INVESTOR PRESENTATION PURPOSES ONLY. Sources
Slide 16: % of Call Effort to Top Decile HCPs
% of Call Effort to Top Decile HCPs Decile 7-10 HCPs represented greater than 50% of all call efforts in September, aligning with rollout of a smaller, yet higher opportunity, target audience receiving increased frequency 60% 50% 40% 31% % of Call Effort 30% Decile 7-10: 53% 20% 10% 22% 0% Jun Jul A
Slide 17: ANNOVERA Monthly TRx
ANNOVERA Monthly TRx +14% vs. Prior 3 Months 3,200 2,800 2,400 2,000 TRx 1,600 1,200 800 400 0 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Month FOR INVESTOR PRESENTATION PURPOSES ONLY. Source: Symphony PHAST – September 2021 17
Slide 18: ANNOVERA Quarterly TRx
ANNOVERA Quarterly TRx 9,000 +14% 8,000 7,000 6,000 5,000 TRx 4,000 8,351 7,299 3,000 5,935 6,319 5,133 2,000 1,000 0 Q320 Q420 Q121 Q221 Q321 Quarter FOR INVESTOR PRESENTATION PURPOSES ONLY. Source: Symphony PHAST – September 2021 18
Slide 19: ANNOVERA Prescribers: Launch to Date
ANNOVERA Prescribers: Launch to Date 10,000 9,000 1,306 8,000 Cumulative Prescribers 1,409 7,000 6,000 1,554 5,000 1,439 4,000 8,147 6,738 3,000 1,514 5,184 2,000 750 3,745 1,000 947 2,231 1,481 529 5 534 0 Q419 Q120 Q220 Q320 Q420 Q121 Q221 Q321 Quarter Existing Rxers New Rxers Source: Symphony PHA
Slide 20: IMVEXXY Quarterly TRx
IMVEXXY Quarterly TRx Held up well considering prioritization on ANNOVERA in Q3 Full targeting and mix assessment to be completed Q4 2021 140,000 120,000 100,000 80,000 TRx 60,000 40,000 20,000 0 Q320 Q420 Q121 Q221 Q321 Quarter Source: Symphony PHAST – September 2021 FOR INVESTOR PRESENTATION P
Slide 21: Accelerators for Q4 and Beyond
Accelerators for Q4 and Beyond 2 J Code assigned Allows ANNOVERA access in Public Health sector 3 Twenty-two newly filled territories 2 High potential areas In field first week of October 3 1 Significant managed care wins 1 Major sources of Prior Authorizations Increase covered lives by
Slide 22: Q&A
Q&A FOR INVESTOR PRESENTATION PURPOSES ONLY.